Abstract
SEL-212 is a developmental treatment for uncontrolled gout characterized by serum uric acid (sUA) levels ≥ 6mg/dl despite treatment. It comprises a novel PEGylated uricase (SEL-037; also called pegadricase) co-administered with tolerogenic nanoparticles containing sirolimus (rapamycin) (SEL-110; also called ImmTOR®), which mitigates the formation of anti-drug antibodies (ADAs) against uricase and SEL-037 (PEGylated uricase), thereby enabling sustained sUA control (sUA < 6mg/dl). The aim of this study was to identify appropriate dosing for SEL-037 and SEL-110 for use in phase 3 clinical trials. This open-label phase 2 study was conducted in adults with symptomatic gout and sUA ≥ 6mg/dl. Participants received five monthly infusions of SEL-037 (0.2 or 0.4mg/kg) alone or in combination with three or five monthly infusions of SEL-110 (0.05-0.15mg/kg). Safety, tolerability, sUA, ADAs, and tophi were monitored for 6months. A total of 152 adults completed the study. SEL-037 alone resulted in rapid sUA reductions that were not sustained beyond 30days in most participants due to ADA formation and loss of uricase activity. Levels of ADAs decreased with increasing doses of SEL-110 up to 0.1mg/kg, with anti-uricase titers < 1080 correlating with sustained sUA control and reductions in tophi. Overall, 66% of evaluable participants achieved sUA control at week 20 following five monthly doses of SEL-037 0.2mg/kg + SEL-110 0.1-0.15mg/kg, whereas only 26% achieved sUA control at week 20 when SEL-110 was withdrawn after week 12. Compared to other dose combinations, SEL-037 0.2mg/kg + SEL-110 0.15mg/kg achieved the greatest sUA control at week 12 and was well-tolerated with no safety concerns. Results provide continued support for the use of multiple monthly administrations of SEL-037 0.2mg/kg + SEL-110 0.1-0.15mg/kg in clinical trials for SEL-212. ClinicalTrials.gov identifier, NCT02959918.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
